Bavarian Nordic company profile

BAVA · Nasdaq Copenhagen · DKK

Compare Bavarian Nordic
kr 241.00Change from previous close: +0.67%Absolute change: +kr 1.60

Close · November 17, 2026

Company profile

Bavarian Nordic has 1,692 employees and is headquartered in Hellerup, Denmark.

With 1,692 employees, the company develops, makes and sells vaccines against smallpox, monkeypox, rabies, tick-borne encephalitis, cholera and typhoid fever, including the JYNNEOS, IMVANEX, Rabipur and Vaxchora products. It is also running a phase 2 trial of MVA-BN WEV for encephalitis viruses. Its markets include the United States, Canada, Germany, Japan, Australia and Saudi Arabia, along with several European countries and other regions in its international business.

The group reported revenue of DKK 6.2 billion in the fiscal year ended December 2025, a rise of 9.2% from the year before, and net profit of DKK 1.4 billion for the same period. Founded in 1992, it has its seat in Hellerup, Denmark.

Company facts

Industry
Biotechnology
Country
Denmark
Headquarters
Philip Heymans Alle 3, 2900, Hellerup
Employees
1,692
Chief executive
Paul Chaplin
Founded
1992
Fiscal year
January - December
Listing
BAVA · Nasdaq Copenhagen
Currency
DKK
ISIN
DK0015998017

Bavarian Nordic and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Bavarian NordicBAVADenmark$2.64B1,6926.9%12.4
BioArcticBIOA.BSweden$2.72B15019.6%262.7
Zealand PharmaZEALDenmark$2.36B60559.0%5.49
Lakefront BiotherapeuticsLKFTNetherlands$2.28B19657.5%2.62
CamurusCAMXSweden$4.36B32337.4%58.5
IdorsiaIDIASwitzerland$1.25B424-68.4%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Bavarian Nordic with its competitors